EMMA (Emmaus Life Sciences) Institutional Ownership: 0.64% (As of Jul. 06, 2026)


What is Emmaus Life Sciences Institutional Ownership?

Emmaus Life Sciences EMMA +5.26% Institutional Ownership is 0.64% as of Jul. 06, 2026. The stock has 6 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Emmaus Life Sciences's institutional ownership is 0.64%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Emmaus Life Sciences's Insider Ownership is 67.67%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Emmaus Life Sciences's Float Percentage Of Total Shares Outstanding is 73.87%.

Emmaus Life Sciences Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Emmaus Life Sciences's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Emmaus Life Sciences Institutional Ownership Chart

Emmaus Life Sciences Historical Data

The historical data trend for Emmaus Life Sciences can be seen below:

2020-10-31 2020-11-30 2020-12-31 2021-01-31 2021-02-28 2021-03-31 2021-04-30 2021-05-31 2021-06-30 2021-07-31
Institutional Ownership 0.62 0.62 0.62 0.62 0.62 0.62 0.62 0.64 0.64 0.64

Emmaus Life Sciences Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 0.64% mean?
Emmaus Life Sciences (EMMA) has a Institutional Ownership of 0.64% as of Jul. 06, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Emmaus Life Sciences and its competitors.
Is Emmaus Life Sciences' Institutional Ownership too high?
Emmaus Life Sciences' current Institutional Ownership is 0.64%.
How does Emmaus Life Sciences' Institutional Ownership compare to PTIX and BZYR?
Emmaus Life Sciences' Institutional Ownership of 0.64% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Emmaus Life Sciences and its competitors. Emmaus Life Sciences's current Institutional Ownership is 0.64%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emmaus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Emmaus Life Sciences (EMMA) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading 14.2% above its estimated fair value. The current Institutional Ownership is 0.64%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Emmaus Life Sciences (EMMA), the current Institutional Ownership is 0.64% as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Emmaus Life Sciences Business Description

Address 21250 Hawthorne Boulevard, Suite 800, Torrance, CA, USA, 90503
Emmaus Life Sciences Inc is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sales of the Company's product Endari (prescription grade L-glutamine oral powder), to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. Endari is reimbursable by the Centers for Medicare and Medicaid Services, and every state provides coverage for Endari for outpatient prescriptions to all eligible Medicaid enrollees within their state Medicaid programs. Endari is also reimbursable by many commercial payors.